Fazelian, S. and Moradi, F. and Agah, S. and Hoseini, A. and Heydari, H. and Morvaridzadeh, M. and Omidi, A. and Pizarro, A.B. and Ghafouri, A. and Heshmati, J. (2021) Effect of omega-3 fatty acids supplementation on cardio-metabolic and oxidative stress parameters in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology, 22 (1).
|
Text
Effect of omega-3 fatty acids supplementation on cardio-metabolic and oxidative stress parameters in patients with chronic kidney disease a systematic review and meta-analysis.pdf Download (1MB) | Preview |
Abstract
Background: Omega-3 fatty acids (FAs) have been suggested as a beneficial supplement in chronic kidney disease (CKD) patients, but the results of randomized clinical trials (RCTs) are controversial. We conducted a systematic review and meta-analysis to evaluate all the RCTs about the impact of omega-3 FAs supplementation on cardiometabolic outcomes and oxidative stress parameters in patients with CKD. Methods: We performed a systematic database search in PubMed/MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Central, up to May 2020. We included all placebo-controlled randomized trials that assessed the effect of omega-3 FAs supplementation on any cardiometabolic outcomes: blood pressure, total cholesterol (TC), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) or triglycerides (TG) and oxidative stress parameters. Data were pooled using DerSimonian�Laird�s random-effects model. Results: Finally, thirteen articles met the inclusion criteria for this review omega-3 FAs supplementation significantly decrease TC (SMD: -0.26; 95 CI: � 0.51, � 0.02; I2 = 52.7), TG (SMD: -0.22; 95 CI: � 0.43, � 0.02; I2 = 36.0) and Malondialdehyde (MDA) levels (SMD: -0.91; 95 CI: � 1.29, � 0.54; I2 = 00.0) and also significantly increase superoxide dismutase (SOD) (SMD: 0.58; 95 CI: 0.27, 0.90; I2 = 00.0) and Glutathione peroxidase (GPx) (SMD: 0.50; 95 CI: 0.14, 0.86; I2 = 00.0) activities. However our results show that omega-3 FAs supplementation have no significant effects on HDL, LDL and blood pressure. Conclusion This systematic review and meta-analysis supports current evidence for the clinical benefit of omega-3 FAs intake to improve cardiometabolic parameters in CKD patients. However, well-designed RCTs still needed to provide a conclusive picture in this field. © 2021, The Author(s).
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 0 |
| Uncontrolled Keywords: | cholesterol; glutathione peroxidase; high density lipoprotein; low density lipoprotein; malonaldehyde; omega 3 fatty acid; superoxide dismutase; triacylglycerol, Article; blood pressure; cardiometabolic risk; cholesterol blood level; chronic kidney failure; clinical feature; diet supplementation; human; meta analysis; oxidative stress; patient risk; risk factor; systematic review; triacylglycerol blood level |
| Subjects: | WJ Urogenital System QV Pharmacology |
| Depositing User: | eprints admin |
| Date Deposited: | 08 Aug 2021 06:27 |
| Last Modified: | 08 Aug 2021 06:27 |
| URI: | http://eprints.iums.ac.ir/id/eprint/38869 |
Actions (login required)
 |
View Item |
